References
- Mutnick AH, Biedenback DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn Microbiol Infect Dis 2002; 43: 66–73
- Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001; 61: 525–51
- Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use programme. Clin Infect Dis 2003; 36: 159–68
- Howden BP, Ward PB, Charles PGP, Korman TM, Fuller A, Du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521–8
- Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Shentag JJ. Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 2004; 32: 8–14
- Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicentre study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980–92
- Vinken AG, Li JZ, Balan DA, Rittenhouse BE, Willke RJ, Goodman C. Comparison of linezolid with oxacillin or vancomycin in the empirical treatment of cellulitis in US Hospitals. Am J Ther 2003; 10: 264–74
- Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopaedic infections. Mayo Clin Proc 2004; 79: 1137–44
- Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53: 345–55
- Ravindran V, John J, Kaye GC, Meigh RE. Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J Infect 2003; 47: 164–6
- Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747–50
- Kutscha-Lisssberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964–6
- Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving haemodyalisis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000; 31: 208–9
- Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop 2004; 427: 67–71
- Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin Drug Saf 2004; 3: 405–14
- Nathwani D, Li JZ, Balan DA, Willke RJ, Rittenhouse BE, Mozaffari E, et al. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents 2004; 23: 315–24